CL2015002412A1 - Composición farmacéutica sólida de daptomicina; método de fabricación; y uso para tratar infecciones bacterianas (divisional de la sol. 1336-2012) - Google Patents
Composición farmacéutica sólida de daptomicina; método de fabricación; y uso para tratar infecciones bacterianas (divisional de la sol. 1336-2012)Info
- Publication number
- CL2015002412A1 CL2015002412A1 CL2015002412A CL2015002412A CL2015002412A1 CL 2015002412 A1 CL2015002412 A1 CL 2015002412A1 CL 2015002412 A CL2015002412 A CL 2015002412A CL 2015002412 A CL2015002412 A CL 2015002412A CL 2015002412 A1 CL2015002412 A1 CL 2015002412A1
- Authority
- CL
- Chile
- Prior art keywords
- daptomycin
- pharmaceutical composition
- solid pharmaceutical
- composition
- solid
- Prior art date
Links
- 108010013198 Daptomycin Proteins 0.000 title abstract 10
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical group C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 title abstract 10
- 229960005484 daptomycin Drugs 0.000 title abstract 10
- 239000007787 solid Substances 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 208000035143 Bacterial infection Diseases 0.000 title abstract 2
- 208000022362 bacterial infectious disease Diseases 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000008247 solid mixture Substances 0.000 abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
SE REFIERE A UNA COMPOSICIÓN SOLIDA DE DAPTOMICINA DONDE UNA CANTIDAD DE IA COMPOSICION FARMACÉUTICA SÓLIDA DE DAPTOMICINA QUE CONTIENE 500 MG DE DAPTOMICINA SE DISUELVE EN 10 ML DE CLORURO DE SODIO ACUOSO AL 0.9% EN MENOS DE 5 MINUTOS A ALREDEDOR DE 25°C DONDE LA COMPOSICION FARMACÉUTICA SOLIDA DE DAPTOMICINA SE OBTIENE POR: A. FORMACION DE UNA SOLUCION ACUOSA DE DAPTOMICINA QUE COMPRENDE DAPTOMICINA A UN PH DE ALREDEDOR DE 4,5-8,0, Y B. CONVE RSION DE IA SOLUCION ACUOSA DE DAPTOMICINA EN IA COMPOSICION FARMACÉUTICA SÓLIDA DE DAPTOMICINA. TAMBIÉN SE RELACIONA CON UN PRODUCTO FARMACÉUTICO QUE COMPRENDE LA COMPOSICION SOLIDA DE DAPTOMICINA; EL MÉTODO DE FABRICACIÓN DE LA COMPOSICION FARMACÉUTICA SOLIDA, Y EL USO PARA EL TRATAMIENTO DE INFECCIONES BACTERIANAS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26378409P | 2009-11-23 | 2009-11-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015002412A1 true CL2015002412A1 (es) | 2016-02-05 |
Family
ID=44060422
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2012001336A CL2012001336A1 (es) | 2009-11-23 | 2012-05-23 | Composicion farmaceutica solida de daptomicina preparada por liofilizacion de una solucion acuosa que comprende daptomicina y al menos un excipiente seleccionado de glicina y un azucar no reductor con un ph de 6,5-7,5; producto farmaceutico; metodo de fabricacion; uso para tratar infecciones bacterianas. |
| CL2015002412A CL2015002412A1 (es) | 2009-11-23 | 2015-08-27 | Composición farmacéutica sólida de daptomicina; método de fabricación; y uso para tratar infecciones bacterianas (divisional de la sol. 1336-2012) |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2012001336A CL2012001336A1 (es) | 2009-11-23 | 2012-05-23 | Composicion farmaceutica solida de daptomicina preparada por liofilizacion de una solucion acuosa que comprende daptomicina y al menos un excipiente seleccionado de glicina y un azucar no reductor con un ph de 6,5-7,5; producto farmaceutico; metodo de fabricacion; uso para tratar infecciones bacterianas. |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US8835382B2 (es) |
| EP (2) | EP3417849A1 (es) |
| JP (3) | JP6041673B2 (es) |
| CN (3) | CN104056250A (es) |
| AR (2) | AR079127A1 (es) |
| AU (1) | AU2010321531C1 (es) |
| BR (1) | BR112012012406B1 (es) |
| CA (1) | CA2781666C (es) |
| CL (2) | CL2012001336A1 (es) |
| CO (1) | CO6541585A2 (es) |
| CR (1) | CR20120271A (es) |
| CY (1) | CY1120854T1 (es) |
| DK (1) | DK2504353T4 (es) |
| DO (1) | DOP2012000140A (es) |
| EC (1) | ECSP12011939A (es) |
| ES (1) | ES2686331T5 (es) |
| FI (1) | FI2504353T4 (es) |
| HR (1) | HRP20181380T4 (es) |
| HU (1) | HUE039967T2 (es) |
| IL (1) | IL219891B (es) |
| LT (1) | LT2504353T (es) |
| MX (1) | MX2012005993A (es) |
| NZ (1) | NZ600118A (es) |
| PE (2) | PE20121517A1 (es) |
| PL (1) | PL2504353T5 (es) |
| PT (1) | PT2504353T (es) |
| RS (1) | RS57566B2 (es) |
| RU (1) | RU2607526C2 (es) |
| SG (1) | SG10201407724YA (es) |
| SI (1) | SI2504353T2 (es) |
| TR (1) | TR201812823T4 (es) |
| TW (2) | TWI548414B (es) |
| WO (1) | WO2011063419A2 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6696412B1 (en) | 2000-01-20 | 2004-02-24 | Cubist Pharmaceuticals, Inc. | High purity lipopeptides, Lipopeptide micelles and processes for preparing same |
| US20060014674A1 (en) | 2000-12-18 | 2006-01-19 | Dennis Keith | Methods for preparing purified lipopeptides |
| PE20121517A1 (es) | 2009-11-23 | 2012-11-26 | Cubist Pharm Inc | Compuestos lipopeptidos y metodos relacionados |
| TW201309346A (zh) | 2011-01-05 | 2013-03-01 | Hospira Inc | 噴霧乾燥萬古黴素 |
| BR112013030369A2 (pt) * | 2011-05-26 | 2016-12-13 | Cubist Pharm Inc | composições de cb-183,315 e métodos relacionados |
| CN104168908A (zh) * | 2012-01-12 | 2014-11-26 | 细胞基因公司 | 罗米地新制剂及其用途 |
| US20150216928A1 (en) * | 2012-08-23 | 2015-08-06 | Agila Special Ties Private Limited | Daptomycin injectable formulation |
| DK2895187T1 (da) | 2012-09-11 | 2015-11-16 | Hospira Australia Pty Ltd | Daptomycinformuleringer og anvendelser deraf |
| CN104027791B (zh) * | 2013-03-06 | 2016-08-10 | 浙江海正药业股份有限公司 | 药物组合物 |
| CN104511011A (zh) * | 2013-09-29 | 2015-04-15 | 山东新时代药业有限公司 | 一种达托霉素无菌粉末及其制备方法 |
| US10647746B2 (en) | 2016-04-08 | 2020-05-12 | Versitech Limited | Antibacterial cyclic lipopeptides |
| US11667674B2 (en) | 2016-04-08 | 2023-06-06 | Versitech Limited | Antibacterial cyclic lipopeptides |
| ES2946600T3 (es) | 2016-10-21 | 2023-07-21 | Xellia Pharmaceuticals Aps | Formulaciones líquidas de daptomicina |
| MX2020001885A (es) * | 2017-08-31 | 2020-09-07 | Xellia Pharmaceuticals Aps | Formulaciones de daptomicina. |
| CN110339341A (zh) * | 2018-04-03 | 2019-10-18 | 江苏恒瑞医药股份有限公司 | 一种达托霉素或其盐的组合物 |
| CN110548130A (zh) * | 2018-06-04 | 2019-12-10 | 浙江医药股份有限公司新昌制药厂 | 含达托霉素的喷雾干粉及其工业化制备方法 |
| US11058745B1 (en) | 2018-10-04 | 2021-07-13 | Good Health, Llc | Stable liquid pharmaceutical compositions of daptomycin |
| CN111840511A (zh) * | 2019-04-30 | 2020-10-30 | 江苏恒瑞医药股份有限公司 | 一种含有精氨酸的达托霉素或其盐的组合物 |
| CN114828873A (zh) * | 2019-12-26 | 2022-07-29 | 尼普洛株式会社 | 含有达托霉素的稳定的冷冻干燥制剂 |
| CN115038431B (zh) | 2020-02-28 | 2024-08-09 | 埃克斯利亚制药有限公司 | 达托霉素制剂 |
| JP2023517926A (ja) | 2020-03-12 | 2023-04-27 | バクスター・インターナショナル・インコーポレイテッド | ソルビトールとマンニトールの組み合わせを含むダプトマイシン製剤 |
| US11362190B2 (en) | 2020-05-22 | 2022-06-14 | Raytheon Company | Depletion mode high electron mobility field effect transistor (HEMT) semiconductor device having beryllium doped Schottky contact layers |
| KR102218688B1 (ko) * | 2020-06-25 | 2021-02-22 | 주식회사 클린텍 | 무선제어기능을 구비한 고압세척기 |
| RU2770481C1 (ru) * | 2021-06-25 | 2022-04-18 | федеральное государственное автономное образовательное учреждение высшего образования «Казанский (Приволжский) федеральный университет» (ФГАОУ ВО КФУ) | Способ получения суммарной фракции липопептидов бактерий Bacillus subtilis MG-8 ВКПМ В-12476 и его использование в качестве профилактического средства от болезней сельскохозяйственных птиц |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331594A (en) | 1978-10-16 | 1982-05-25 | Eli Lilly And Company | A-21978 Antibiotics and process for their production |
| EP0014815A3 (de) | 1978-12-20 | 1980-10-29 | Ciba-Geigy Ag | Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen |
| US4432487A (en) | 1982-01-18 | 1984-02-21 | Chugai Denki Kogyo Kabushiki Kaisha | Method of overlaying stainless steel material for decorative articles and ornaments with a precious metal alloy |
| US4482487A (en) | 1982-05-21 | 1984-11-13 | Eli Lilly And Company | A-21978C cyclic peptides |
| US4537717A (en) | 1982-05-21 | 1985-08-27 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
| PT81265B (pt) | 1984-10-09 | 1988-02-17 | Lilly Co Eli | Processo aperfeicoado para a producao de antibioticos derivados do peptideo ciclico a-21978c |
| CA1319886C (en) | 1987-02-03 | 1993-07-06 | Alberto Ferro | Mixed micelle solutions |
| ZA883887B (en) | 1987-06-10 | 1990-02-28 | Lilly Co Eli | Chromatographic purification process |
| EP0294990A3 (en) | 1987-06-10 | 1990-05-09 | Eli Lilly And Company | Chromatographic purification process |
| US4874843A (en) | 1987-12-03 | 1989-10-17 | Eli Lilly And Company | Chromatographic purification process |
| US5271935A (en) | 1988-02-05 | 1993-12-21 | Hoechst Aktiengesellschaft | Antibiotic, cammunocin, a process for the preparation thereof, and the use thereof as a pharmaceutical |
| ZA901622B (en) * | 1989-03-06 | 1991-11-27 | Lilly Co Eli | An improved diluent formulation for daptomycin |
| ES2110405T3 (es) | 1990-01-26 | 1998-02-16 | Hoechst Ag | Un nuevo antibiotico, desoximulundocandina, un procedimiento para su produccion y su uso como medicamento. |
| JPH04224197A (ja) | 1990-12-26 | 1992-08-13 | Fujitsu Ltd | 生体高分子結晶化方法および装置 |
| US5336756A (en) | 1991-05-01 | 1994-08-09 | Merck & Co., Inc. | Process for crystalline cyclic lipopeptides |
| TW213468B (es) | 1991-06-29 | 1993-09-21 | Hoechst Ag | |
| JP2948708B2 (ja) | 1991-11-27 | 1999-09-13 | ニューヨーク・ブラッド・センター・インコーポレーテッド | フィブロネクチン含有点眼液 |
| DE69319428T2 (de) | 1992-04-20 | 1999-02-04 | Abbott Laboratories, Abbott Park, Ill. | Verfahren zur herstellung von vancomycin |
| TW455591B (en) | 1993-06-08 | 2001-09-21 | Hoechst Ag | Lipopeptides from actinoplanes sp. with pharmacological action, process for their production and the use thereof |
| DE4411025A1 (de) | 1994-03-30 | 1995-10-05 | Hoechst Ag | Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung |
| US5952300A (en) | 1996-04-19 | 1999-09-14 | Merck & Co., Inc. | Antifungal compositions |
| US5955509A (en) | 1996-05-01 | 1999-09-21 | Board Of Regents, The University Of Texas System | pH dependent polymer micelles |
| JPH10212241A (ja) | 1996-05-27 | 1998-08-11 | Sumitomo Pharmaceut Co Ltd | Ｂｄｎｆを安定に含有する製剤 |
| AU5528198A (en) | 1997-12-03 | 1999-06-16 | Immune Response Corporation, The | Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides |
| FR2771640B1 (fr) | 1997-12-03 | 2000-02-11 | Inst Nat Sante Rech Med | Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques |
| FR2774687B1 (fr) | 1998-02-06 | 2002-03-22 | Inst Nat Sante Rech Med | Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques |
| DE19807972A1 (de) | 1998-02-25 | 1999-08-26 | Hoechst Marion Roussel De Gmbh | Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung |
| SI1115417T1 (sl) | 1998-09-25 | 2006-08-31 | Cubist Pharm Inc | Uporaba daptomicina |
| US7279597B1 (en) | 1999-11-05 | 2007-10-09 | Emisphere Technologies, Inc. | Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| US7129274B1 (en) | 1999-11-05 | 2006-10-31 | Emisphere Technologies Inc. | Phenoxy carboxylic acid compounds and compositions for delivering active agents |
| US7408025B2 (en) | 1999-12-15 | 2008-08-05 | Cubist Pharmaceuticals, Inc. | Lipopeptides as antibacterial agents |
| US6696412B1 (en) | 2000-01-20 | 2004-02-24 | Cubist Pharmaceuticals, Inc. | High purity lipopeptides, Lipopeptide micelles and processes for preparing same |
| ES2394926T3 (es) * | 2000-06-21 | 2013-02-06 | Cubist Pharmaceuticals, Inc. | Composiciones para mejorar la absorción oral de agentes antimicrobianos |
| US6716962B2 (en) | 2000-07-17 | 2004-04-06 | Micrologix Biotech Inc. | Extractive purification of lipopeptide antibiotics |
| US20060014674A1 (en) | 2000-12-18 | 2006-01-19 | Dennis Keith | Methods for preparing purified lipopeptides |
| WO2002059145A1 (en) | 2000-12-18 | 2002-08-01 | Cubist Pharmaceuticals, Inc. | Methods for preparing purified lipopeptides |
| KR20110127732A (ko) | 2000-12-18 | 2011-11-25 | 큐비스트 파마슈티컬즈 인코포레이티드 | 정제된 리포펩티드의 제조 방법 |
| US20080220441A1 (en) | 2001-05-16 | 2008-09-11 | Birnbaum Eva R | Advanced drug development and manufacturing |
| JP3932272B2 (ja) * | 2001-06-28 | 2007-06-20 | 明治乳業株式会社 | 多重ｔ細胞エピトープポリペプチドの酢酸塩組成物 |
| US20030113316A1 (en) | 2001-07-25 | 2003-06-19 | Kaisheva Elizabet A. | Stable lyophilized pharmaceutical formulation of IgG antibodies |
| US20050027113A1 (en) | 2001-08-06 | 2005-02-03 | Miao Vivian Pak Woon | Compositions and methods relating to the daptomycin biosynthetic gene cluster |
| AU2003216726A1 (en) | 2002-01-17 | 2003-07-30 | Atofina | Supramolecular polymers |
| WO2004004658A2 (en) | 2002-07-09 | 2004-01-15 | Point Therapeutics, Inc. | Methods and compositions relating to isoleucine boroproline compounds |
| US8216609B2 (en) | 2002-08-05 | 2012-07-10 | Torrent Pharmaceuticals Limited | Modified release composition of highly soluble drugs |
| US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| US8268352B2 (en) | 2002-08-05 | 2012-09-18 | Torrent Pharmaceuticals Limited | Modified release composition for highly soluble drugs |
| US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
| US8912174B2 (en) | 2003-04-16 | 2014-12-16 | Mylan Pharmaceuticals Inc. | Formulations and methods for treating rhinosinusitis |
| JP2005060377A (ja) * | 2003-07-28 | 2005-03-10 | Yamanouchi Pharmaceut Co Ltd | インターロイキン−１１含有凍結乾燥製剤 |
| US20050152979A1 (en) * | 2003-09-05 | 2005-07-14 | Cell Therapeutics, Inc. | Hydrophobic drug compositions containing reconstitution enhancer |
| US20050196418A1 (en) | 2004-03-04 | 2005-09-08 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
| CN1616083A (zh) * | 2004-09-01 | 2005-05-18 | 魏雪纹 | 注射用达托霉素冻干制剂及制备方法 |
| ES2482700T3 (es) * | 2005-02-14 | 2014-08-04 | Venus Remedies Limited | Terapia de combinación parenteral para enfermedades infecciosas causadas por una bacteria resistente a los medicamentos |
| CA2610716A1 (en) | 2005-05-31 | 2006-12-07 | Cubist Pharmaceuticals, Inc. | Daptomycin for the treatment of biofilm and catheter salvage |
| AU2006339311A1 (en) | 2005-06-07 | 2007-09-07 | Foamix Ltd. | Antibiotic kit and composition and uses thereof |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| PL2049142T5 (pl) * | 2006-07-26 | 2016-09-30 | Sandoz Ag | Preparaty kaspofunginy |
| EP2084519B1 (en) | 2006-10-10 | 2012-08-01 | Los Alamos National Security, LLC | X-ray fluorescence analysis method |
| DE102007004968B4 (de) * | 2007-01-26 | 2011-03-10 | Heraeus Kulzer Gmbh | Revisions-Polymethylmethacrylat-Knochenzement |
| WO2008102452A1 (ja) | 2007-02-22 | 2008-08-28 | Kringle Pharma Inc. | Ｈｇｆ製剤 |
| CA2687246A1 (en) * | 2007-06-01 | 2008-12-11 | Acologix, Inc. | High temperature stable peptide formulation |
| AU2008269140A1 (en) | 2007-06-26 | 2008-12-31 | Merck Sharp & Dohme Corp. | Lyophilized anti-fungal composition |
| EP2207584A2 (en) * | 2007-10-25 | 2010-07-21 | Novartis Ag | Powder conditioning of unit dose drug packages |
| WO2009144739A1 (en) | 2008-05-26 | 2009-12-03 | Biocon Limited | Amorphous daptomycin and a method of purification thereof |
| WO2011019839A2 (en) | 2009-08-12 | 2011-02-17 | The Medicines Company | Glycopeptide and lipoglycopeptide antibiotics with improved solubility |
| US8431539B2 (en) | 2009-09-17 | 2013-04-30 | Eagle Pharmaceuticals, Inc. | Formulations of daptomycin |
| PE20121517A1 (es) | 2009-11-23 | 2012-11-26 | Cubist Pharm Inc | Compuestos lipopeptidos y metodos relacionados |
| WO2011062676A1 (en) | 2009-11-23 | 2011-05-26 | Eagle Pharmaceuticals, Inc. | Formulations of daptomycin |
| WO2012061360A2 (en) | 2010-11-01 | 2012-05-10 | Rib-X Pharmaceuticals, Inc. | Pharmaceutical compositions |
| ES2661574T3 (es) | 2010-12-23 | 2018-04-02 | Alkermes Pharma Ireland Limited | Profármacos de carga de múltiples PAF |
| US20130034597A1 (en) | 2011-02-04 | 2013-02-07 | Aegis Therapeutics Llc | Orally bioavailable peptide drug compositions and methods thereof |
-
2010
- 2010-11-23 PE PE2012000703A patent/PE20121517A1/es active IP Right Grant
- 2010-11-23 AU AU2010321531A patent/AU2010321531C1/en active Active
- 2010-11-23 PL PL10832379.1T patent/PL2504353T5/pl unknown
- 2010-11-23 BR BR112012012406-4A patent/BR112012012406B1/pt active IP Right Grant
- 2010-11-23 TR TR2018/12823T patent/TR201812823T4/tr unknown
- 2010-11-23 WO PCT/US2010/057910 patent/WO2011063419A2/en active Application Filing
- 2010-11-23 US US13/511,246 patent/US8835382B2/en active Active
- 2010-11-23 PE PE2015002039A patent/PE20151717A1/es unknown
- 2010-11-23 CN CN201410208415.8A patent/CN104056250A/zh active Pending
- 2010-11-23 DK DK10832379.1T patent/DK2504353T4/da active
- 2010-11-23 CN CN201080062122.3A patent/CN102712677B/zh active Active
- 2010-11-23 ES ES10832379T patent/ES2686331T5/es active Active
- 2010-11-23 TW TW099140485A patent/TWI548414B/zh active
- 2010-11-23 EP EP18181723.0A patent/EP3417849A1/en not_active Withdrawn
- 2010-11-23 MX MX2012005993A patent/MX2012005993A/es unknown
- 2010-11-23 LT LTEP10832379.1T patent/LT2504353T/lt unknown
- 2010-11-23 FI FIEP10832379.1T patent/FI2504353T4/fi active
- 2010-11-23 RS RS20180974A patent/RS57566B2/sr unknown
- 2010-11-23 HU HUE10832379A patent/HUE039967T2/hu unknown
- 2010-11-23 HR HRP20181380TT patent/HRP20181380T4/hr unknown
- 2010-11-23 NZ NZ600118A patent/NZ600118A/en unknown
- 2010-11-23 PT PT10832379T patent/PT2504353T/pt unknown
- 2010-11-23 SG SG10201407724YA patent/SG10201407724YA/en unknown
- 2010-11-23 JP JP2012540161A patent/JP6041673B2/ja active Active
- 2010-11-23 CA CA2781666A patent/CA2781666C/en active Active
- 2010-11-23 AR ARP100104318 patent/AR079127A1/es not_active Application Discontinuation
- 2010-11-23 SI SI201031736T patent/SI2504353T2/sl unknown
- 2010-11-23 CN CN201810651754.1A patent/CN108785654A/zh active Pending
- 2010-11-23 TW TW105116907A patent/TWI606838B/zh active
- 2010-11-23 RU RU2012126076A patent/RU2607526C2/ru active
- 2010-11-23 EP EP10832379.1A patent/EP2504353B2/en active Active
-
2012
- 2012-05-18 DO DO2012000140A patent/DOP2012000140A/es unknown
- 2012-05-20 IL IL219891A patent/IL219891B/en not_active IP Right Cessation
- 2012-05-22 CR CR20120271A patent/CR20120271A/es unknown
- 2012-05-23 CL CL2012001336A patent/CL2012001336A1/es unknown
- 2012-05-31 EC ECSP12011939 patent/ECSP12011939A/es unknown
- 2012-06-08 CO CO12097444A patent/CO6541585A2/es unknown
-
2013
- 2013-12-04 US US14/096,346 patent/US9138456B2/en active Active
-
2015
- 2015-08-12 US US14/824,272 patent/US9662397B2/en active Active
- 2015-08-27 CL CL2015002412A patent/CL2015002412A1/es unknown
-
2016
- 2016-03-02 JP JP2016039505A patent/JP6088681B2/ja active Active
-
2017
- 2017-02-03 JP JP2017018290A patent/JP6239167B2/ja active Active
-
2018
- 2018-09-04 CY CY181100923T patent/CY1120854T1/el unknown
-
2021
- 2021-10-19 AR ARP210102879A patent/AR123846A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015002412A1 (es) | Composición farmacéutica sólida de daptomicina; método de fabricación; y uso para tratar infecciones bacterianas (divisional de la sol. 1336-2012) | |
| PE20061107A1 (es) | Composiciones de tigeciclina y metodos para su preparacion | |
| EA200702329A1 (ru) | Замещенные пирролпиридины, содержащие их композиции, способ получения и применение | |
| EA201101192A1 (ru) | Фармацевтическая композиция, включающая производные глюкопиранозилдифенилметана, фармацевтическая дозированная форма, содержащая указанные производные, способ их получения и применения для улучшения гликемического контроля у пациентов | |
| EA201200551A1 (ru) | Фармацевтическая композиция, фармацевтическая дозированная форма, способы их получения и применения для лечения | |
| NZ612503A (en) | Method for producing an aqueous stable chlorine dioxide solution | |
| PE20080374A1 (es) | Composiciones farmaceuticas de ropinirol | |
| EA018193B3 (ru) | Соединения и фармацевтические композиции для снижения уровня мочевой кислоты | |
| CO6382125A2 (es) | Inhibidores de proteína quinasa | |
| ATE470443T1 (de) | Indol-1-yl-essigsäurederivate | |
| MX2009005413A (es) | Formas cristalinas del acido zoledronico. | |
| RU2012155188A (ru) | Композиции для ухода за полостью рта, устойчивые к микробному росту | |
| MA34100B1 (fr) | Compositions d'argile | |
| EA201200519A1 (ru) | Стабилизированные жидкие и лиофилизированные композиции adamts13 | |
| EA201071167A1 (ru) | Стабилизированные олеосомные композиции и способы их получения | |
| EA200801580A1 (ru) | Новые производные пирониндола и способ их получения | |
| MX2012003615A (es) | Composiciones de limpieza abrasivas, acidas, viscosas. | |
| BRPI0911678B8 (pt) | maleato de orvepitant cristalino anidro, composição farmacêutica compreedendo o dito maleato e uso do mesmo para o tratamento ou profilaxia de doenças do sistema nervoso central | |
| MX2009006325A (es) | Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales. | |
| EA201270573A1 (ru) | Гранулированный в расплаве цинакальцет | |
| BRPI0509667A (pt) | azaquinazolinas substituìdas com eficácia antiviral | |
| PE20130374A1 (es) | Composicion farmaceutica que comprende ibuprofeno | |
| AR077915A1 (es) | Forma cristalina de pemirolast | |
| MY150201A (en) | Cosmetic composition for external adminstration in spray form | |
| NZ591529A (en) | Chemical composition for skin care formulations |